Introduction: The UK Renal Association clinical practice guidelines include clinical performance measures for biochemical variables in dialysis patients. The UK Renal Registry (UKRR) annually audits dialysis centre performance against these measures as part of its role in promoting continuous quality improvement. Methods: Cross sectional performance analyses were undertaken to compare dialysis centre achievement of clinical audit measures for prevalent haemodialysis (HD) and peritoneal dialysis (PD) cohorts in 2012. The biochemical variables studied were phosphate, adjusted calcium, parathyroid hormone, bicarbonate and total cholesterol. In addition, longitudinal analyses were performed (2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012) to show changes in achievement of clinical performance measures over time. Results: Fifty-six percent of HD and 61% of PD patients achieved a phosphate within the range recommended by the RA clinical practice guidelines. Seventy-seven percent of HD and 78% of PD patients had adjusted calcium between 2.2-2.5 mmol/L. Fifty-eight percent of HD and 65% of PD patients had parathyroid hormone between 16-72 pmol/L. Fifty-nine percent of HD and 80% of PD patients achieved the audit measure for bicarbonate. There was significant inter-centre variation for all variables studied. Conclusions: The UKRR consistently demonstrates significant inter-centre variation in achievement of biochemical clinical audit measures. Understanding the causes of this variation is an important part of improving the care of dialysis patients in the UK.
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Introduction
The UK Renal Registry (UKRR) collects routine biochemical data from clinical information systems in renal centres in England, Wales and Northern Ireland and receives data from Scotland via the Scottish Renal Registry. Annual cross sectional analyses are undertaken on some of these variables to determine centre level performance against national (Renal Association) clinical performance measures [1] . This enables UK renal centres to compare their own performance against each other and to the UK average performance [2] . Currently the 5th edition of the UK Renal Association clinical practice guidelines is in practice [1] . This edition commenced in a graded manner in 2009 and includes an expanded number of guideline modules compared to previous editions.
Audit measures for kidney disease increasingly include tighter specification limits in conjunction with a growing evidence base. Out of range observations (e.g. hyperphosphataemia and hypophosphataemia) need to be interpreted cautiously as they may relate to different clinical problems or population characteristics. These will therefore require different strategies to improve centre performance of clinical audit measures. To supplement these performance analyses, summary statistical data have been provided to enhance understanding of the population characteristics of each centre and longitudinal analyses demonstrate changes over time.
Methods
These analyses relate to biochemical variables in the prevalent dialysis cohort in England, Wales and Northern Ireland in 2012. Scotland is also included in analyses pertaining to phosphate control. The cohort studied were patients prevalent on dialysis treatment on 31st December 2012, excluding patients receiving dialysis for less than 90 days and those who had changed modality or renal centre in the last 90 days. Haemodialysis (HD) and peritoneal dialysis (PD) cohorts were analysed separately. A full definition of this cohort including inclusion and exclusion criteria is included in appendix B www.renalreg.com.
The biochemical variables analysed were phosphate, calcium, parathyroid hormone, bicarbonate and cholesterol. The method of data collection and validation by the UKRR has been described elsewhere [3] . For each quarter of 2012 the UKRR extracted biochemical data electronically from clinical information systems in UK dialysis centres. The UKRR does not collect data regarding different assay methods mainly because a single dialysis centre may process samples in several different laboratories. Scottish centres have only been included in analyses relating to phosphate control, with data for their prevalent dialysis cohort being supplied directly by the Scottish Renal Registry. The audit measure used for serum phosphate was 1.1-1.7 mmol/L in both the HD and PD cohorts [1, 3] . For centres providing adjusted calcium values, these data were analysed directly as it is these values on which clinical decisions within centres are based. For centres providing unadjusted calcium values, a formula in widespread use was used to calculate adjusted calcium [4] . The audit measure for adjusted calcium depends on a local reference range [1, 3] . The UKRR has used the RA guideline standard of adjusted calcium between 2.2-2.5 mmol/L as the audit measure for these analyses. There are also a variety of methods and reference ranges in use to measure parathyroid hormone (PTH). To enable some form of comparative audit the UKRR has used 2-9 times the median upper limit of the reference range (8 pmol/L) as the audit measure in line with the 5th edition of the Renal Association clinical practice guidelines that were current during 2012 and KDIGO 2009 guidance [3, 5] . This equates to a PTH of 16-72 pmol/L. The audit measure used for serum bicarbonate in the HD cohort was 18-24 mmol/L as per the updated haemodialysis guidelines and in the PD cohort was 22-30 mmol/L [1] . A summary of the current Renal Association audit measures and conversion factors to SI units are given in table 12.1.
Quarterly values were extracted from the database for the last two quarters for calcium, phosphate and bicarbonate; the last three quarters for PTH and the entire year for cholesterol. Patients who did not have these data were excluded from the analyses. Data completeness was analysed at centre and country level. All patients were included in analyses but centres with less than 50% completeness were excluded from plots showing centre level performance. Data were also excluded from plots when there were less than 20 patients with data both at centre or country level. These data were analysed to calculate summary descriptive statistics (maximum, minimum, mean and median values in addition to standard deviation and quartile ranges). Where applicable, the percentage achieving the Renal Association standard or other surrogate clinical performance measure was also calculated.
The simultaneous control of all three components of bone and mineral disorder (BMD) parameters were analysed in combination. Thus, the control of none, one, two or three parameters, as well as an analysis of combinations of calcium-PTH, calciumphosphate and phosphate-PTH were collated, with an emphasis on evaluating the effective management and prevention of severe hyperparathyroidism (maintaining PTH 72 pmol/L). For the purpose of this analysis, the corrected calcium standard of between 2.2-2.5 mmol/L, a phosphate level being maintained at or below 1.7 mmol/L and a PTH level being at or below 72 pmol/L, were evaluated in combination.
The analyses presented in this chapter are descriptive. As data are provided unadjusted for confounding factors and due to concerns regarding measurement error in many of the biochemical parameters, hypothesis testing was not utilised.
Centres report several biochemical variables with different levels of accuracy, leading to problems in comparative evaluation. For example, in the case of serum bicarbonate, data can be submitted as integer values but some centres submit data to one decimal place. All data has been rounded up in an attempt to make all centres more comparable.
The number preceding the centre name in each figure indicates the percentage of missing data for that centre. Funnel plot analysis was used to identify 'outlying centres' [6] . The percentage achieving each standard was plotted against centre size along with the upper and lower 95% and 99.9% limits. Centres can be identified on these plots by looking up the number of patients treated in each centre provided in the relevant table and finding this value on the x-axis. Longitudinal analyses were performed for some data to calculate overall changes in achievement of a performance measure annually from 2002 to 2012 and were recalculated for each previous year using the rounding procedure. All data were unadjusted for case-mix.
Results and discussions

Mineral and bone variables Phosphate
In 2012 the following Renal Association clinical practice guideline regarding phosphate management was applicable:
Guideline 3.2 CKD-MBD: Serum phosphate in dialysis patients ' We suggest that serum phosphate in dialysis patients, measured before a ''short-gap'' dialysis session in haemodialysis patients, should be maintained between 1.1 and 1.7 mmol/L (2C)' [3] The data completeness for serum phosphate across the UK was 96% for HD patients and 98% for PD patients although there was considerable variation between centres (tables 12.2 and 12.4). There was significant between centre variation in the proportion of patients below, within and above the phosphate range specified by the clinical performance measure (figures 12.1-12.4). Of note, the percentage of PD patients achieving the target decreased substantially from 2011 for Birmingham Heartlands (from 66% to 43%) and for Cambridge (from 72% to 47%). The same fall was not seen for HD patients at these centres. If the phosphate analyses for both HD and PD patients were conducted in the same laboratories for each centre, it suggests that this was not due to any change in laboratory methods.
Adjusted calcium
In 2012, the following Renal Association clinical practice guideline regarding calcium management was applicable: Guideline 2.2 CKD-MBD: Serum calcium in dialysis patients (stage 5D) ' We suggest that serum calcium, adjusted for albumin concentration, should be maintained within the normal reference range for the laboratory used, measured before a ''short-gap'' dialysis session in haemodialysis patients. Ideally, adjusted serum calcium should be maintained between 2.2 and 2.5 mmol/L, with avoidance of hypercalcaemic episodes (2D)' [3] The current guidelines are based upon adjusted serum calcium. A variety of formulae have been proposed to permit calculation of the 'adjusted' total calcium (i.e. an
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Nephron Clin Pract 2013;125:219-258 estimation of the expected total calcium were the serum albumin normal) from the total calcium and albumin concentration, but there are no data to support the use of mathematical corrections of serum calcium amongst patients with ERF. This topic was discussed in considerable detail in the 2009 report and most of the shortcomings remain. However the ongoing restructuring of pathology into a smaller number of services together with harmonisation should increase measurement uniformity across laboratories and hence renal centres. UK laboratories are still in the process of adopting the guidelines to harmonise albumin-adjusted calcium reference ranges to 2.2-2.6 mmol/L using method-specific adjustment equations normalised to a mean calcium of 2.4 mmol/L. Until this process is complete, differences between laboratories in the reported adjusted calcium are likely to continue. Meanwhile, centres must work with their laboratories to ensure that the calcium results are adjusted correctly for the methods in use. These problems must be borne in mind when trying to interpret the following figures that compare serum adjusted calcium achieved in different renal centres. These issues raise the question as to whether these comparisons between centres of achievement of the calcium guidelines are of value, and also raises questions about the guidelines themselves. To try and better understand the varation in current laboratory assays utilised and practice in adjustment formulae applied it is proposed to undertake a short survey of all renal centres in 2013.
The audit measure for calcium in the current Renal Association clinical practice guidelines does not specify a lower limit for calcium and advises that adjusted calcium should ideally be within the normal range as per earlier guidance. Previously the UKRR used 2.2-2.5 mmol/L as the audit measure for adjusted calcium and in the absence of any change in guidance has maintained this range in this report to allow consistency. The data for adjusted calcium was 97% complete for HD patients and 98% complete for PD patients overall, although there was between centre variation (tables 12.6, Similar to that seen in earlier phosphate analyses, there was significant between centre variation in unadjusted analyses for the proportion of patients below, within and above the range specified by the clinical performance measure (figures 12.6-12.10). There was greater variation in the proportion of patients within range for adjusted calcium than phosphate, most notably for HD patients. The funnel plot shows a greater number of centres outlying the 3SD limit indicating over dispersion in the data, possibly due to differences in calcium adjustment factors between centres.
Parathyroid hormone
At the beginning of 2012 the following RA guideline for PTH applied: Guideline 4.2.1 CKD-MBD: Target range of serum PTH in patients on dialysis ' We suggest that the target range for parathyroid hormone measured using an intact PTH assay should be between 2 and 9 times the upper limit of normal for the assay used (2C)' [3] The data for parathyroid hormone were 83% complete for both HD and PD patients overall, although there was between centre variation (tables 12.10, 12.12). Fifty-eight percent (95% CI 57-58%) of HD patients and 65% (95% CI 63-67%) of PD patients achieved a parathyroid hormone between 16-72 pmol/L (tables 12.11, 12.13). In 2010, when the PTH standard target was 16-32 pmol/L, 28% (95% CI 27-29%) of HD patients and 31% (95% CI 29-32%) of PD patients achieved the RA standard.
In 2012, the proportion of HD patients with a parathyroid hormone above the upper limit of the range (.72 pmol/L) was 16% and the proportion with parathyroid hormone below the lower limit of the range was 27%. The proportion of PD patients with parathyroid hormone above the upper limit of the range was 10% and the proportion below the lower limit of the range was 25% (tables 12.11, 12.13, figures 12.11-12.14). Again there was significant between centre variation in unadjusted analyses for the proportion of patients below, within and above the range specified by the clinical performance measure.
A significant contributor to centre variation will be the assay used to measure PTH. This has been demonstrated by a study undertaken by the Scottish Clinical Biochemistry Managed Diagnostic Network in association with the Scottish Renal Registry. Analysis of samples from 106 haemodialysis patients by six different PTH immunoassays in common use showed a 1.2-to 2.7-fold variation in results in spite of similar reference ranges for each method [7] . Since current guidelines refer to multiples of the upper reference limit, 53% of Blank cells denote centres excluded from analyses due to low patient numbers or poor data completeness In an excellent accompanying editorial, Garrett and Goldsmith [8] also highlighted the high biological variability of PTH and its poor ability to predict skeletal or patient outcomes. Whether more accurate and specific assays would improve this or whether PTH will be supplanted by other markers such as bone specific alkaline phosphatase that also have greater pre-analytical stability remains to be determined [9] . Improvement of PTH assays to achieve consensus results within CKD patients requires manufacturers to consider two principal factors: adoption of a common reference preparation for standardisation, such as the WHO international standard 95/646, and selection of pairs of antibodies that do not detect PTH fragments such as 7-84 that accumulate in CKD. Meanwhile Almond et al. [7] and a recent editorial review [10] urge adoption of assay-specific action limits for PTH in CKD patients. However this approach raises a number of difficult governance issues. There is already evidence that the manufacturers of the major diagnostic platforms used throughout the world have started to respond. The Roche assay used by Almond et al. [7] was PTH (intact) that was not standardised and cross-reacted with PTH 7-84. Roche have recently launched the more expensive PTH (1-84) that is standardised against the WHO international standard 95/646 and has 0.1% cross-reactivity with both PTH (1-34) and PTH (7-84) (information supplied by Roche Diagnostics).
Simultaneous control of corrected calcium, phosphate and PTH in preventing severe hyperparathyroidism Data points to perform the bone mineral disease (BMD) combination analyses were available from 58 HD and 45 PD centres, covering 16,300 HD and 2,377 PD patients, from England, Wales and Northern Ireland. The ranges used for this audit were adjusted calcium 2. [11] [12] [13] [14] [15] . A recent cohort study has demonstrated that simultaneous achievement of all three audit measures does appear to be associated with better outcomes [16] . The UKRR has consistently demonstrated between centre variation in achievement of audit measures for bone and mineral parameters but little is understood about the causes of this 'centre effect'. The complexity of the clinical processes required to manage mineral and bone disorders is probably further confounded by case-mix. In the future, with centres moving to newer IT systems, medications used in the management of bone and mineral diseases may become available to aid in better analyses of these parameters.
Finally, it is important to consider data quality and the potential for measurement bias particularly in light of the variability in assay methods for parathyroid hormone as discussed above. However, detecting these centre level differences is an important step in understanding the factors associated with exceptional performance.
Bicarbonate
In 2012 the following Renal Association clinical practice guidelines regarding bicarbonate management were applicable: Haemodialysis Guideline 6.3: Pre-dialysis serum bicarbonate concentrations 'We suggest that pre-dialysis serum bicarbonate concentrations, measured with minimum delay after venepuncture, should be between 18 and 24 mmol/l. (2C)' [17] Peritoneal Dialysis Guideline 6.2 -PD: Metabolic factors ' We recommend that plasma bicarbonate should be maintained within the normal range' [18] Citing evidence for reduced risk of adverse events, the haemodialysis module of the 5th edition of the Renal Association clinical practice guidelines published in December 2009 [1, [17] [18] recommended a target range for serum bicarbonate of 18-24 mmol/L, a reduction from the previous guideline range of 20- 12.18, 12.20) . The UKRR has previously conducted a limited survey into the possible underlying causes of this variation. The study predominantly looked at measures of sample processing and of dialysis treatment. It did not adjust for case-mix and was unable to detect any significant differences between centres. However, it is possible that there may be unmeasured processes including dialysis and oral bicarbonate prescription that might account for the variation observed [19] .
Total cholesterol
There is no audit standard for total cholesterol in the Renal Association clinical practice guidelines. Current guidance on lipid management states:
'We recommend that statins (or 3 hydroxy-3 methylglutaryl-coenzyme A reductase inhibitors) should be considered for primary prevention in all CKD Stages 1-4 and transplant patients with a 10-year risk of cardiovascular disease, calculated as >20% according to the Joint British Societies' Guidelines -JBS2 (British Hypertension Society British Cardiac Society 2005).
We recommend that a total cholesterol of <4 mmol/L or a 25% reduction from baseline, or a fasting low density lipoprotein (LDL)-cholesterol of <2 mmol/L or a 30% reduction from baseline, should be achieved, whichever is the greatest reduction in all patients.
Statins should not be withdrawn from patients in whom they were previously indicated and should continue to be prescribed when such patients start renal replacement therapy (RRT) or change modality.' [20] Total cholesterol data were 82% complete for HD patients and 78% complete for PD patients. As there are no specific audit measures for total cholesterol, summary data are presented for each dialysis centre (tables 12.21, 12.22, figures 12.21, 12.22 ). There are a number of case-mix factors (comorbidity, inflammation, 
